CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has proved helpful conscientiously but unsuccessfully to create an one-time therapy, variously called Pro 140, leronlimab, and Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in terms of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll actually be used is actually an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as a combination therapy in the therapy of multi-drug-resistant HIV happen to be closing.

I’m creating my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of the past several shares of mine. The 1st CytoDyn article of mine, “CytoDyn: What In order to Do When It is Too Good to be able to Be True?”, set out what follows prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan offered such a very promotional image in the Uptick Newswire interview which I came away with an inadequate impression of the company.

Irony of irony, the poor impression of mine of the company has grown steadily, though the disappointment has not been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger at the moment still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much storied treatment (which I shall relate to as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the therapy as well as avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity in HIV infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of the technology and associated intellectual property from Progenics to CytoDyn, as well as roughly 25 million mg of bulk drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 million) plus the first brand new drug application approval ($five million), as well as royalty payments of 5 percent of net sales after commercialization.

Since that point in time, CytoDyn’s helping nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to purchase a market place cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous indications and many therapies, it’s this single therapies in addition to a “broad pipeline of indications” since it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a potentially beneficial therapy in dozens of indications.

Its opening banner on the site of its (below) shows an energetic organization with diverse interests albeit centered on leronlimab, multiple disease sorts, multiple delivering presentations in addition to multiple publications.

Could all this be smoke and mirrors? That is a question I have been asking myself from the very beginning of my interest in this particular company. Judging with the multiples of a huge number of various remarks on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am far from alone in this question.

CytoDyn is a classic battleground, or some could say cult stock. Its adherents are fiercely shielding of its prospects, quick to label any negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News